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Screening of REarranged during Transfection (RET) gene mutations has been carried out in different series of sporadic medullary
thyroid carcinomas (MTC). RET-positive tumours seem to be associated to a worse clinical outcome. However, the correlation
between the type of RET mutation and the patients’ clinicopathological data has not been evaluated yet.
We analysed RET exons 5, 8, 10–16 in fifty-one sporadic MTC, and found somatic mutations in thirty-three (64.7%) tumours. Among
the RET-positive cases, exon 16 was the most frequently affected (60.6%). Two novel somatic mutations (Cys630Gly, c.1881del18)
were identified. MTC patients were divided into three groups: group 1, with mutations in RET exons 15 and 16; group 2, with other
RET mutations; group 3, having no RET mutations. Group 1 had higher prevalence (P¼0.0051) and number of lymph node
metastases (P¼0.0017), and presented more often multifocal tumours (P¼0.037) and persistent disease at last control (P¼0.0242)
than group 2. Detectable serum calcitonin levels at last screening (P¼0.0119) and stage IV disease (P¼0.0145) were more frequent
in group 1, than in the other groups.
Our results suggest that, among the sporadic MTC, cases with RET mutations in exons 15 and 16 are associated with the
worst prognosis. Cases with other RET mutations have the most indolent course, and those with no RET mutations have an
intermediate risk.
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Medullary thyroid carcinoma (MTC) is a rare tumour that
represents 5–10% of all types of thyroid cancer, and accounts
for a disproportionate number of thyroid cancer deaths (Hundahl
et al, 1998). Except for surgery, therapy for MTC is generally
ineffective. MTC may occur sporadically (in about 75% of cases) or
as a part of the autosomal dominantly inherited cancer syndrome,
known as multiple endocrine neoplasia type 2 (MEN 2) (Mulligan
et al, 1993; Eng, 1999; Frank-Raue et al, 2007). MTC is the most
common cause of death in patients with MEN 2 (Skinner et al,
2005). This familial type of thyroid carcinoma usually originates as
multifocal C-cell hyperplasia, its progression to MTC is extremely
variable, and may take several years (Carling, 2005). In sporadic
cases, the mean age at presentation is 50 years, with a slight female
predominance (Matias-Guiu et al, 2004).
Activating germline mutations in the REarranged during
Transfection (RET) gene are detected in over 95% of MEN 2 cases
(Mulligan et al, 1993; Marx, 2005). The oncogenic potential of
different RET mutations seems to be dependent on the site of the
amino acid change, and may account for the diverse phenotypes
observed in MEN 2 patients (Asai et al, 1995).
The screening of RET mutations has been carried out in
different series of sporadic MTC, however the observed frequen-
cies are variable (12–100%) (Hofstra et al, 1994; Zedenius et al,
1994; Jhiang et al, 1996; Marsh et al, 1996, 2003; Romei et al, 1996;
Wohllk et al, 1996; Bugalho et al, 1997; Scurini et al, 1998; Shan
et al, 1998; Uchino et al, 1998, 1999; Bockhorn et al, 1999;
Dvorakova et al, 2008; Elisei et al, 2008). Met918Thr RET mutation
is the most common somatic mutation in sporadic forms of MTC,
and its detection rate varies greatly (5–66%) in the published
literature (Zedenius et al, 1994; Marsh et al, 1996; Romei et al,
1996; Wohllk et al, 1996; Bugalho et al, 1997; Scurini et al, 1998;
Uchino et al, 1998, 1999; Dvorakova et al, 2008; Elisei et al, 2008).
However, in some of these studies, the authors have screened
sporadic MTC for only a few specific mutations, mostly in codon
918 (Hofstra et al, 1994; Shan et al, 1998; Bockhorn et al, 1999;
Marsh et al, 2003). Therefore, the number of exons screened, as
well as the sizes of the analysed series, may explain some of the
reported differences in the prevalence of RET mutations in
sporadic MTC. In addition, ethnic or environmental factors,
differences in detection or in sampling methods may also account
for the reported differences (Uchino et al, 1998; Dvorakova et al,
2008). In some cohorts, besides the Met918Thr mutation, other
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ssomatic mutations were also detected, at a lower frequency in
exons 10, 11, 12, 13 and 15 (Bugalho et al, 1997; Scurini et al, 1998;
Uchino et al, 1999).
The major somatic mutation (Met918Thr) localised in the
tyrosine kinase domain in exon 16 of RET (Marini et al, 2006) has
been associated to a worse clinical outcome in sporadic MTC when
compared with tumours that did not harbour this mutation
(Zedenius et al, 1994, 1995; Wohllk et al, 1996; Schilling et al,
2001).
Several reports have presented contradictory results concerning
the ploidy pattern in MTC. Schro ¨der et al (1988) found that most
MTC have a diploid DNA pattern, and that a benign disease course
was twice as frequent in patients with diploid tumours compared
with aneuploid tumours. Conversely, the results presented by
Lindsay (1970) seemed to be more consistent with aneuploidy in
MTC.
In this study, we carried out a comprehensive analysis of exons
5, 8 and 10–16 of RET to evaluate the prevalence of somatic
mutations in a series of fifty-one sporadic MTC and to correlate
with clinicopathological characteristics of the patients, including
tumour ploidy pattern.
MATERIALS AND METHODS
Patients
A total of fifty-two unrelated patients with MTC without family
history of the disease were studied for RET mutations. A detailed
personal history was obtained from all patients. All individuals
were of Caucasian origin (34 females and 18 males). Each patient
underwent total thyroidectomy, with the exception of two patients
who were submitted to partial thyroidectomy. The diagnosis of
MTC was confirmed by histopathology of the surgically removed
tumours. The Tumour-Node-Metastases (TNM) classification of all
tumour specimens was carried out after the criteria described in
the WHO classification of thyroid tumours (DeLellis et al, 2004).
Stage grouping was addressed according to the TNM classification
(Sobin and Wittekind, 2002), namely, stage I (T1N0M0), stage II
(T2N0M0), stage III (T3N0M0 or T1-T3N1aM0) and stage IV
(T1-T3N1bM0, T4N0-N1M0 or T1-T4N0-N1M1).
The number of truly sporadic MTC patients was reduced to fifty-
one, as a germline mutation was found in one case.
Eight of the fifty-one cases (Table 1, patients 10, 15, 34, 35, 36,
38, 43 and 45) were earlier published by our group (Bugalho et al,
1997, 2000).
This study was carried out following guidelines approved by the
local institution ethical board.
DNA flow cytometry
DNA flow cytometry analysis was carried out on paraffin-
embedded material, according to the method of Hedley et al
(1983), with slight modifications (Andre ´ et al, 2007).
Serum calcitonin measurements
Serum calcitonin (CT) levels were determined using a solid-phase,
enzyme-labelled, two-site chemiluminescent immunoenzymatic
assay (Immulite 2000 Calcitonin, Siemens Medical Solutions
Diagnostic Ltd., Llanberis, Gwynedd, UK) with the Immulite
2000 Automated Analyser (Siemens Medical Solutions Diagnostic
Ltd.). CT values o2.0ngl
–1 were regarded as undetectable.
RET variant analysis
DNA was extracted from tumour samples frozen in liquid nitrogen
(n¼47) following standard protocols. Otherwise, DNA was
isolated from formalin-fixed paraffin-embedded tumour tissues
(n¼5), as described earlier (Imyanitov et al, 2001). Exons 5, 8 and
10 through 16 of RET were amplified by PCR. Sequences of the
oligonucleotide primers and amplification conditions are available
on request. Sequencing was carried out in both sense and antisense
directions, using the same primers as for PCR amplification and
the ABI PRISM BigDye Terminator version 1.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA), in an automated
DNA sequencer (ABI PRISM 310 Genetic Analyser, Applied
Biosystems). All the mutations identified were confirmed by two
independent experiments (restriction enzyme analysis, or repeated
sequence analysis). To support somatic origin of the mutations,
constitutional DNA from peripheral blood or non-tumourous
tissue from the same patient was also analysed.
Statistical analysis
The statistical analysis was accomplished using GraphPad
Prism version 4.0 statistical software (GraphPad Software Inc.,
San Diego, CA, USA) and SPSS 13.0 for Windows (SPSS Inc.,
Chicago, IL, USA). Values were expressed as mean±s.e.m.
The w
2 or Fisher’s exact tests, and one-way analysis of
variance or Kruskal–Wallis test were used according to the
studied variables. Survival curves were analysed using the
Kaplan–Meier method, and the statistical significance was
assessed by the logrank test. Values of Po0.05 were considered
statistically significant.
RESULTS
Genetic analysis
One out of the fifty-two (1.9%) cases of clinically apparently
sporadic MTC carried a new germline mutation (Cys515Trp)
located in exon 8 (manuscript under preparation). This case was
excluded from further analysis.
In the remaining fifty-one sporadic MTC cases, thirty-three
(64.7%) had mutations in RET exons 10, 11, 15 and 16 (Table 2).
The absence of these mutations in the constitutional DNA
excluded a germline origin.
Among the RET-positive cases, exon 16 was the most frequently
affected (60.6%) by the same specific Met918Thr mutation,
followed by exon 11 (21.2%). RET mutations were also detected
in exons 10 (9.1%) and 15 (9.1%). In the present series, two novel
RET mutations (Cys630Gly and c.1881del18) located at exon 11
were identified. The novel Cys630Gly variant creates a restriction
site for the enzyme BsrI, facilitating its independent confirmation
(data not shown). The other novel variant (c.1881del18) is
expected to lead to the replacement of seven amino acid residues
by a glutamic acid residue. In this case, PCR amplification
originated two fragments: the expected wild-type product (322bp)
and a smaller mutant product (304bp), allowing the independent
sequencing of both alleles (data not shown). Together with this
mutation, and in the same allele, an unreported heterozygous
nucleotide change in codon 634 (TGC to TGT) that does not
predict an amino acid alteration (Cys to Cys) was found (data not
shown).
In the MTC tissue of patient 51, with a Cys618Arg mutation
(Table 1), the wild-type allele was not detected. The finding of
allelic loss at flanking markers D10S141 and ZNF22 showed
hemizygosity for this mutation (data not shown).
No mutations were identified in the other analysed exons,
namely, exons 5, 8, 12, 13 or 14 (Table 2).
Forty-four (86.3%) tumours displayed a diploid DNA content
and seven (13.7%) were aneuploid. No correlation between the
presence or type of RET mutation and the ploidy pattern was
observed (Table 3).
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sClinical evaluation
Table 1 describes the clinical and pathological data of the fifty-one
patients with sporadic MTC.
In the thirty-three MTC patients (19 females and 14 males)
carrying somatic RET mutations, the mean age at surgery and
mean follow-up time were 52.9 years (median 55, range 26–71)
and 94.8 months (median 100, range 4–303), respectively. Lymph
node and distant metastases were present in 23/33 (69.7%) and
11/31 (35.5%) cases, respectively. According to the TNM
classification, four patients (12.1%) had stage I disease, three
(9.1%) had stage II, two (6.1%) had stage III and twenty-four
(72.7%) had stage IV. At the time of the last clinical screening, nine
patients (29.0%) were free of disease, and twenty-two (71.0%) were
non-disease free (seven of them were deceased from MTC). The
status at last control from two patients was not available. Among
the twenty-two patients with persistent disease, ten (47.6%)
showed a biochemical persistence of the disease with detectable
levels of serum CT, but no evidence of distant metastases, whereas
eleven patients (52.4%) were affected by metastatic disease.
Clinical data from one case were not available.
As regard to the eighteen MTC patients (14 females and 4 males)
without somatic RET mutation, the mean age at surgery and mean
follow-up were 55.8 years (median 59.5, range 27–82) and 90.8
months (median 73.5, range 0.6–252), respectively. Lymph node
and distant metastases were present in 11/18 (61.1%) and 3/18
Table 1 Clinical and genetic findings in fifty-one patients with sporadic MTC
Patient
no. Sex
RET
somatic
mutation
MTC
presentation
Age at
surgery
(years)
Tumour
size
a
(cm)
Post-oper.
serum CT
(ngl
–1)
Serum CT
at last
control
(ngl
–1)
TNM
classification
at last
control
No. of
positive
lymph nodes
Overall
survival
(months)
Disease free
survival
(months)
Status
at last
control
Extragl.
ext.
Vasc.
inv. Multif.
Ploidy
pattern
1F c.1881del18+
Cys634Cys
TN 50 1.5 19.4 132.0 T1N1bM0 5 149 0 NDF No NA No D
2 F Neg TN 50 2 Undetect. Undetect. T1N0M0 0 172 172 DF No No No D
3M Cys630Gly TN 71 6 1290.0 5647.0 T4aN0MX 0 74 0 NDF Yes Yes No D
4 M Neg TN 69 12 449.8 53341.0 T4bN1aM0 2 196 0 NDF Yes Yes No D
5 M Met918Thr TN+LN 69 7 1610.0 14594.0 T4bmN1bM1 19 Dec/9 0 NDF Yes Yes Yes D
6 F Met918Thr TN+LN 59 3.5 869.0 16209.0 T2N1bM1 7 167 0 NDF No NA No D
7 F Met918Thr TN 39 5 2.2 9361.0 T3N1bM0 20 303 24 NDF NA NA No D
8 F Neg LN 77 3.5 NA NA T4aN1bM0 18 18 days 0 NDF Yes NA No D
9 M Neg TN+LN 59 7 265.0 1162.0 T4aN1bM1 2 Dec/35 0 NDF Yes Yes No A (1.86)
10 M Met918Thr LN 58 3.5 NA NA T4amN1bM0 410 0 0 NA Yes Yes Yes D
11 F Neg LN 46 10 418.2 88512.0 T4aN1bM1 17 Dec/29 0 NDF Yes NA No D
12 F Ala883Phe TN+LN 59 4.5 16493.0 158014.0 T4amN1bM1 410 Dec/32 0 NDF Yes Yes Yes D
13 F Met918Thr TN 53 2.1 68.9 97706.0 T2N1aM1 0 Dec/12 0 NDF No NA No D
14 F Met918Thr TN 49 4 86.6 833.0 T2N1bM0 18 143 0 NDF No Yes No D
15 F Cys634Arg TN 67 3.5 179.4 81.7 T2N0M0 0 141 0 NDF No Yes No D
16 F Neg TN 60 5.5 261.0 Undetect. T3N1aM0 1 79 79 DF No No No D
17 F Met918Thr TN+LN 26 3 NA NA T2mN1bMX 18 NA NA NA No Yes Yes D
18 M Cys620Ser TN 31 1.8 7.8 Undetect. T1N0M0 0 124 124 DF No No No D
19 M Ala883Phe TN+LN 55 5 110.5 33800.0 T3mN1bM1 10 Dec/85 0 NDF No Yes Yes D
20 F Neg TN 72 8.5 12.3 823.0 T3mN1bM0 12 49 0 NDF No NA Yes D
21 M Met918Thr TN+LN 49 2 141.0 3999.0 T4aN1bM0 7 56 0 NDF Yes NA No A (1.65)
22 M Met918Thr TN 71 4.5 8525.0 14584.0 T4amN1bM0 37 11 0 NDF Yes Yes Yes D
23 F Neg TN 27 NA NA 78.3 TXN1bM0 NA 252 0 NDF NA NA NA D
24 M Cys620Arg TN 70 4.5 6.5 Undetect. T3N1bM0 3 61 61 DF No NA NA A (1.93)
25 F Met918Thr TN+LN 66 4 Undetect. Undetect. T2N1bM0 3 70 70 DF No No No D
26
b F Neg TN 47 3.5 Undetect. Undetect. T2N0M0 0 72 72 DF No No No A (1.95)
27 F Met918Thr TN 50 1.7 84.8 25.9 T4aN1aM0 6 45 0 NDF Yes Yes NA D
28 F Neg TN 61 3 Undetect. Undetect. T2N0M0 0 48 48 DF No No No D
29 M Met918Thr LN 43 2.5 60307.0 103334.0 T2N1bM1 30 41 0 NDF No No No D
30 F Cys634Arg TN 71 1.6 Undetect. Undetect. T1N0M0 0 46 46 DF No NA No D
31 F Cys630Arg TN 67 4.3 Undetect. Undetect. T3N0M0 0 113 113 DF No No No A (1.97)
32 F Met918Thr LN 60 0.8 1234.0 1205.0 T1N1bM0 8 103 0 NDF No NA No D
33 F Neg TN 61 3.5 47.5 Undetect. T2N0M0 0 177 177 DF No No No D
34 F Cys630Arg TN 62 2.5 10.4 Undetect. T2N0M0 0 178 178 DF No No No D
35 M Met918Thr TN 67 3 8.5 15725.0 T2mN1bM0 8 146 0 NDF No No Yes D
36 M Met918Thr TN 29 5 36.4 Undetect. T3N0M0 0 135 135 DF No Yes No A (1.83)
37 F Neg TN+LN 77 8 2582.0 17732.0 T3N1bM1 8 119 0 NDF No Yes No D
38 F Met918Thr TN 57 2.5 8.8 10.6 T2N0M0 0 132 132 NDF No No No D
39 F Met918Thr TN 32 1.7 Undetect. Undetect. T1N0M0 0 121 121 DF No No No D
40 F Met918Thr LN 51 2.3 1970.0 9953.0 T4amN1bM1 10 21 0 NDF Yes No Yes A (1.86)
41
b F Neg TN 27 3 Undetect. Undetect. T2N0M0 0 100 100 DF No Yes No D
42 F Neg NA 82 1.2 Undetect. Undetect. T1N0M0 0 75 75 DF No No No D
43 M Met918Thr LN 29 1.5 36720.0 245000.0 T1mN1bM1 4 Dec/100 0 NDF No No Yes D
44 M Neg TN 40 2 268.0 46.9 T2N1bM0 3 178 0 NDF No Yes No D
45 M Val882Val+Ala883Phe LN 35 10 34342.0 42694.0 T4aN1bM1 27 Dec/94 0 NDF Yes No No D
46 F Cys634Tyr TN 46 2 Undetect. Undetect. T1N0M0 0 123 123 DF No No No D
47 M Met918Thr TN+LN 44 3.5 7400.0 20884.0 T2N1bM1 412 101 0 NDF No NA No D
48 F Neg TN 42 0.9 Undetect. Undetect. T1N0M0 0 16 16 DF No No No D
49 F Neg TN+LN 46 1 89.0 128.0 T3mN1bM0 10 18 0 NDF Yes Yes Yes D
50 M Neg TN+LN 61 5 13762.0 33687.0 T4amN1bM0 16 18 0 NDF Yes Yes Yes D
51 F Cys618Arg TN+LN 61 10 550.0 NA T4aN1bM1 4 Dec/4 0 NDF Yes NA No D
Abbreviations: A¼aneuploid; CT¼calcitonin; D¼diploid; Dec¼deceased from MTC; DF¼disease free; Extragl. ext.¼extraglandular extension; F¼female; LN¼lymph
node; M¼male; MTC¼medullary thyroid carcinomas; Multif.¼multifocality; NA¼not available; NDF¼non-disease free; Neg¼negative for RET mutations; No.¼number;
Post-oper.¼post-operative; RET¼REarranged during Transfection; TN¼thyroid nodule; TNM¼Tumour-Node-Metastases; Undetect.¼undetectable; Vasc. inv.¼vascular
invasion.
a(the biggest).
bPartial thyroidectomy.
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disease, four (22.2%) had stage II, one (5.6%) had stage III and ten
(55.6%) had stage IV, at last control. At the time of the last clinical
screening, eight patients (44.4%) were free of disease and ten
(55.6%) were non-disease free (two of them were deceased from
MTC). Among the ten patients with persistent disease, six (66.7%)
showed a biochemical persistence of the disease but no evidence of
distant metastases, whereas three patients (33.3%) were affected by
metastatic disease. Biochemical data from one case were not
available.
For all these clinical and pathological data, there was no
statistically significant difference between RET-positive and RET-
negative patients. When the survival curves of RET-positive and
RET-negative MTC patients were compared, a lower percentage of
surviving patients was observed in the group with the somatic RET
mutation, although not statistically significant (data not shown).
As the more aggressive RET mutations are in codons 883 and
918, which are classified as level 3 (de Groot et al, 2006), we
compared clinical data of somatic Met918Thr and Ala883Phe RET
mutation cases (group 1; n¼23, 45.1%) vs cases carrying other
somatic RET mutations (group 2; n¼10, 19.6%), or having no RET
mutation (group 3; n¼18, 35.3%) (Table 3).
Group 1 cases (compared with group 2) had higher prevalence
of lymph node metastases (P¼0.0051), higher number of positive
lymph nodes (P¼0.0017), were more frequently multifocal
(P¼0.037) and had more often persistent disease at last control
(P¼0.0242). Moreover, group 1 was more frequently associated
with detectable serum CT levels at the last screening (P¼0.0119),
as well as with stage IV (P¼0.0145; vs stages I–III), than groups 2
and 3.
Serum CT levels at the last control were highest in group 1
(37521±13818ngl
–1), intermediate in group 3 (11501±6028ngl
–1)
and lowest in group 2 (651.2±624.7ngl
–1). However, the
difference was only statistically significant between group 1 and
group 2 patients (Kruskal–Wallis test plus Dunn’s multiple
comparison test, P¼0.0035). Also, the serum CT levels after
surgery were higher in group 1 than in the other groups, but the
difference did not reach statistical significance (group 1:
8096±3517ngl
–1, group 3: 1135±856.5ngl
–1, group 2:
206.4±132.2ngl
–1; Kruskal–Wallis test, P¼0.0628).
Although not statistically significant, there was a trend for a
higher prevalence of distant metastases in group 1.
There was no statistical significant difference between
patients of the different groups regarding the remaining clinico-
pathological characteristics (Table 3). Furthermore, when the
survival curves of MTC patients from the three groups were
evaluated, no significant differences were observed between each
group (data not shown).
DISCUSSION
Medullary thyroid carcinoma is clinically diagnosed as sporadic
when the patient does not present other endocrine tumours, and
when no other cases of MTC, pheochromocytoma or parathyroid
disease are identified in the patient’s family. However, only the
exclusion of germline mutations in the RET proto-oncogene allows
a definitive diagnosis of sporadic MTC.
The herein reported cohort is one of the largest single-country
studies. Fifty-one sporadic MTC were analysed and somatic
mutations were found in thirty-three (64.7%) cases. Two novel
mutations were identified in exon 11 of the RET proto-oncogene,
in two sporadic MTC cases: a heterozygous point mutation at
codon 630 (Cys630Gly), and a 18bp deletion at nucleotide c.1881
associated in the same allele with a silent nucleotide substitution at
codon 634 (Cys634Cys). Both mutations are located in the
cysteine-rich domain coding sequence, which, when mutated, has
been shown to constitutively activate RET (Santoro et al, 1995,
2002).
In this study, eight earlier described missense changes in RET
were detected in exons 10, 11, 15 and 16. In accordance with other
studies, the most common mutation was Met918Thr with a
detection rate of 39.2%, which represents 60.6% of all detected
mutations. In one case, loss of heterozygosity at RET flanking
microsatellite markers was detected, showing hemizygosity for a
sporadic missense mutation (Cys618Arg), a rare genetic event that
has been reported earlier for other RET mutations (Jindrichova
et al, 2003; Dvora ´kova ´ et al, 2006).
As RET mutations other than Met918Thr are rare, most of the
reported series did not compare the clinicopathological character-
istics of Met918Thr vs other RET mutations (Dvorakova et al, 2008;
Elisei et al, 2008). In our study, 13/51 (25.5%) cases had a RET
mutation other than Met918Thr, which allowed such comparison.
On the basis of the recent literature, RET mutations have been
stratified into three risk levels, regarding the predisposition to
originate MTC, as well as their in vitro transforming activity.
Patients with germline mutations in RET codons 883 (exon 15) and
918 (exon 16), for which thyroidectomy is recommended at an
early age, have the highest risk for the early development and the
most aggressive MTC growth (Evans et al, 2007). Likewise, these
two mutations (which are considered as level 3) have the highest
in vitro transforming activity. Therefore, in this study, cases with
Ala883Phe or Met918Thr mutations were analysed in the same
group (group 1), and compared with cases with other somatic RET
mutations (group 2) and cases with no RET mutation (group 3).
A statistically significant correlation was shown between
group 1 and the presence of lymph node metastases, as well as
the number of positive lymph nodes at the time of surgery,
multifocality and a non-disease free status, compared with group
2. This correlation may account for the significantly higher
frequency of patients from group 1 in stage IV and with
detectable serum CT level at last control, compared with
groups 2 and 3, and also for the significantly increased levels of
serum CT at the last control in group 1 cases in comparison
with group 2. Furthermore, such correlation supports the
hypothesis that mutations in RET exons 15 and 16 are related to
a more aggressive behaviour of MTC. This could be explained by
an earlier dissemination of Met918Thr and Ala883Phe cases to
lymph nodes (Table 3). Indeed, 26.1% of MTC cases came to
clinical attention because of lymph nodes in group 1, whereas this
Table 2 RET mutations identified in sporadic MTC cases
Exon Type of alteration
Number of
patients
% of patients
carrying
a RET
somatic mutation
10 TGC4CGC (Cys618Arg)
a 1 9.1%
TGC4CGC (Cys620Arg) 1
TGC4TCC (Cys620Ser) 1
11 TGC4CGC (Cys630Arg) 2 21.2%
TGC4GGC
(Cys630Gly)
1
TGC4CGC (Cys634Arg) 2
TGC4TAC (Cys634Tyr) 1
c.1881del18+
TGC4TGT
(Cys634Cys)
1
15 GCT4TTT(Ala883Phe)+
GTA4GTT (Val882Val)
1 9.1%
GCT4TTT (Ala883Phe) 2
16 ATG4ACG (Met918Thr) 20 60.6%
Abbreviations: MTC¼medullary thyroid carcinomas; RET¼REarranged during
Transfection.
aThis mutation was in the hemizygous status. Mutations were present
only in tumour DNA. The two novel RET proto-oncogene variants are represented in
bold.
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sTable 3 Clinical and pathological characteristics of patients with Met918Thr and Ala883Phe (group 1) vs other RET mutations (group 2) or no mutation
(group 3) in sporadic MTC
Characteristics
Group 1
Met918Thr and
Ala883Phe RET mutation
(n¼23, 45.1%)
Group 2
Other RET mutation
(n¼10, 19.6%)
Group 3
No RET mutation
(n¼18, 35.3%) P-value
Sex 0.2175
a
Female 52.2% (12/23) 70.0% (7/10) 77.8% (14/18)
Male 47.8% (11/23) 30.0% (3/10) 22.2% (4/18)
MTC presentation 0.099
b
Thyroid nodule 39.1% (9/23) 90.0% (9/10) 64.7% (11/17)
Lymph node 26.1% (6/23) 0.0% (0/10) 11.8% (2/17)
Thyroid nodule and lymph node 34.8% (8/23) 10.0% (1/10) 23.5% (4/17)
Age at surgery (years), mean±s.e.m. 50.00±2.80 59.60±4.19 55.78±3.85 0.1835
c
Tumour size (cm), mean±s.e.m. 3.59±0.42 3.77±0.84 4.68±0.81 0.4240
c
Post-operative serum calcitonin 0.132
b
Undetectable 9.5% (2/21) 30.0% (3/10) 37.5% (6/16)
Detectable 90.5% (19/21) 70.0% (7/10) 62.5% (10/16)
Serum calcitonin at last control 0.0119
a
Undetectable 14.3% (3/21) 66.7% (6/9) 47.1% (8/17)
Detectable 85.7% (18/21) 33.3% (3/9) 52.9% (9/17)
T categories 0.664
b
T1 13.0% (3/23) 40.0% (4/10) 17.6% (3/17)
T2 39.1% (9/23) 20.0% (2/10) 29.4% (5/17)
T3 13.0% (3/23) 20.0% (2/10) 23.5% (4/17)
T4 34.8% (8/23) 20.0% (2/10) 29.4% (5/17)
T categories grouping 0.6944
a
T1–T3 65.2% (15/23) 80.0% (8/10) 70.6% (12/17)
T4 34.8% (8/23) 20.0% (2/10) 29.4% (5/17)
Lymph node metastases 0.0051
a
N1 87.0% (20/23) 30.0% (3/10) 61.1% (11/18)
N0 13.0% (3/23) 70.0% (7/10) 38.9% (7/18)
Distant metastases 0.0588
a
M1 45.5% (10/22) 11.1% (1/9) 16.7% (3/18)
M0 54.5% (12/22) 88.9% (8/9) 83.3% (15/18)
Presence of extraglandular extension 36.4% (8/22) 20.0% (2/10) 35.3% (6/17) 0.6314
a
Presence of vascular invasion 52.9% (9/17) 33.3% (2/6) 50.0% (7/14) 0.823
b
Presence of multifocality 40.9% (9/22) 0.0% (0/9) 17.6% (3/17) 0.037
b
Ploidy pattern 0.758
b
Diploid 87.0% (20/23) 80.0% (8/10) 88.9% (16/18)
Aneuploid 13.0% (3/23) 20.0% (2/10) 11.1% (2/18)
Stage 0.065
b
I 4.3% (1/23) 30.0% (3/10) 16.7% (3/18)
II 4.3% (1/23) 20.0% (2/10) 22.2% (4/18)
III 4.3% (1/23) 10.0% (1/10) 5.6% (1/18)
IV 87.0% (20/23) 40.0% (4/10) 55.6% (10/18)
Stage grouping 0.0145
a
I–III 13.0% (3/23) 60.0% (6/10) 44.4% (8/18)
IV 87.0% (20/23) 40.0% (4/10) 55.6% (10/18)
Number of positive lymph nodes,
mean±s.e.m.
11.48±2.09 1.20±0.63 5.24±1.64 0.0017
d
Follow-up (months), mean±s.e.m. 91.8±15.1 101.3±16.9 90.8±17.6 0.9180
c
Status at last control 0.0242
a
Disease free 14.3% (3/21) 60.0% (6/10) 44.4% (8/18)
Non-disease free 85.7% (18/21) 40.0% (4/10) 55.6% (10/18)
Abbreviations: MTC¼medullary thyroid carcinomas; RET¼REarranged during Transfection.
aw
2-test,
bFisher’s exact test,
cOne-way analysis of variance and
dKruskal–Wallis test.
P-values in italics and bold are statistically significant.
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respectively.
The results presented in Table 3 show a trend towards
the stratification of the three groups of sporadic MTC patients
into risk levels on the basis of the statistically significant
clinicopathological characteristics. Group 1 patients are at the
highest risk for aggressive MTC, followed by group 3 at
intermediate risk, and group 2 patients, which present the lowest
risk for a worse clinical outcome. Therefore, our study shows
that RET mutations in exons 15 and 16 are associated with a more
aggressive behaviour of sporadic MTC than other RET mutations,
as it has been shown in vitro, as well as in the hereditary
variants of MTC.
Taken together, these results suggest that the screening of RET
somatic mutations may be helpful in the management of patients
with MTC, according to the presence and type of RET somatic
mutation.
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